ABSTRACT
Expression of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) can predict for clinical outcome of fluoropyrimidine-based therapy and there is every likelihood that relevant tumors will respond. High TP expression was observed in 35 (42%) patients with soft-tissue sarcoma. Seven out of 26 (27%) such patients revealed molecular phenotype prognostically favorable for capecitabine therapy. More clinical research is required to assess the efficacy of capecitabine-based therapy.
Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Biomarkers, Tumor/analysis , Deoxycytidine/analogs & derivatives , Dihydrouracil Dehydrogenase (NADP)/analysis , Sarcoma/drug therapy , Thymidine Phosphorylase/analysis , Thymidylate Synthase/analysis , Adult , Capecitabine , Deoxycytidine/therapeutic use , Female , Fluorouracil/analogs & derivatives , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Sarcoma/enzymology , Treatment OutcomeABSTRACT
Hyperexpression of epidermal growth factor receptor (EGFR) is often identified as unfavorable prognosis for different epithelial cancers. The study was concerned with an attempt of establishing a relationship between EGFR expression, on the one hand, and patient's clinico-morphological status, prognosis and efficacy of chemotherapy for stage III-IV serous ovarian carcinoma, on the other. EGFR hyperexpression predominated in advanced aggressive tumors and involved a significantly shorter period preceding tumor progression. Similarly, overall survival median in patients with EGFR hyperexpression (21+/-4 months) appeared lower than without it (42+/-8 months). In serous ovarian carcinoma stage III-IV, EGFR hyperexpression should be considered sufficient for prognosis of chemotherapy efficacy, pre-progression time and survival.
